Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Dr. Bryan L. Roth to its Scientific Advisory Board. Dr. Roth, a leading researcher in molecular neuropharmacology with over 30 years of experience, aims to develop psychedelics without hallucinogenic effects. He has secured a $27 million grant from the Defense Advanced Research Projects Agency to support the Ultra Large-Scale-Docking program, which identifies compounds that activate serotonin receptors without causing hallucinations. MindMed's CEO expressed confidence in Dr. Roth's expertise to enhance the company's research and development efforts.
MindMed (NASDAQ: MNMD) announces CEO Robert Barrow will speak at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Barrow's interview is scheduled for 11:30am ET on September 30, with a replay available on MindMed's website for 30 days. MindMed focuses on developing psychedelic-inspired therapies aimed at addressing addiction and mental health issues, with a diverse pipeline including substances like psilocybin and MDMA.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced novel findings from ongoing studies presented by Dr. Matthias Liechti at the INSIGHT Conference in Berlin. The research indicates that a 100 mcg dose of LSD produces perceptual effects equivalent to a 20 mg dose of psilocybin, marking the first clinical evidence of their equivalence. Furthermore, psilocybin was deemed safe alongside SSRIs, with escitalopram reducing anxiety without affecting the psychedelic experience. CEO Robert Barrow highlighted the significance of understanding these substances for optimizing treatment programs.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced the participation of CEO Robert Barrow in several upcoming investor conferences. These include the Advances in Mental Health Virtual Conference on Sept. 22, 2021, CIBC's 20th Annual Eastern Institutional Conference on Sept. 23, and 2021 Cantor Virtual Global Healthcare Conference on Sept. 29. MindMed focuses on developing psychedelic-inspired therapies for addiction and mental illness, showcasing an innovative pipeline of treatments. Webcast replays will be available on MindMed's website for 30 days post-presentation.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that CEO Robert Barrow will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company is focused on developing psychedelic-inspired therapies aimed at treating addiction and mental health issues. Management will also engage in one-on-one meetings with institutional investors during the event. A video webcast of the presentation will be available on-demand starting September 13, 2021, at 7:00 AM ET on MindMed's website.
On September 9, 2021, Mind Medicine (MindMed) announced that its Chief Medical Officer, Dr. Daniel R. Karlin, will co-chair the 8th annual Mobile in Clinical Trials Conference virtually on September 27, 2021. The conference aims to enhance the integration of digital technologies in clinical research. Dr. Karlin emphasized the importance of safety, stating that although they preferred in-person interaction, virtual formats can still facilitate knowledge exchange. MindMed is focused on developing psychedelic-inspired therapies for addiction and mental illness, with a diverse pipeline including psilocybin and MDMA.
MindMed (NASDAQ: MNMD) has partnered with BioXcel Therapeutics to publish an international patent application for a system that detects and prevents agitation in predisposed patients. The method utilizes continuous monitoring of physiological and behavioral signals to predict agitation episodes, allowing for early intervention by caregivers. This collaboration aims to enhance patient care and reduce emergency interventions associated with agitation symptoms, ultimately improving outcomes for individuals suffering from neurological and psychiatric conditions.
On August 24, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a collaboration with Forian Inc. (NASDAQ: FORA) to enhance personalized psychiatry for treating anxiety disorders through real-world evidence (RWE) data. This partnership aims to leverage real-world healthcare data to develop precise treatments by understanding individual physiological and environmental factors. MindMed focuses on psychedelic-inspired therapies, with a drug pipeline targeting mental illness and addiction. The initiative underscores the need for tailored mental health solutions amidst the ongoing impacts of the global pandemic.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has joined the Critical Path Institute's Patient-Reported Outcome (PRO) Consortium to enhance medical innovation and regulatory science. This collaboration aims to develop clinical outcome assessments (COAs) for clinical trials. According to Chief Medical Officer Daniel Karlin, the partnership will leverage real-world data to improve clinical evaluation and precision medicine. The PRO consortium supports patient-focused drug development, reinforcing MindMed's commitment to advancing psychedelic-inspired therapies for mental health issues.
MindMed (Nasdaq: MNMD) reported its Q2 2021 financial results, revealing total assets of $194 million as of June 30, including $157 million in cash. The company incurred a net loss of $36 million for the quarter, with $12 million used in operating activities. On the business front, MindMed launched Project Angie for pain treatment with psychedelics and partnered with Nextage Therapeutics to develop a brain-targeting delivery system. Upcoming earnings call is scheduled for August 16, 2021.
